Dexcom Ventures is the corporate venture capital arm of Dexcom, Inc., a pioneer in continuous glucose monitoring technology. It invests in early-stage companies developing sensing technologies, data analytics, remote patient monitoring, and other digital health solutions adjacent to Dexcom's core business.
100% of their portfolio is in Healthcare. Their most common stage is series-a (50% of deals). Average disclosed round size is $42.9M (across 6 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
Jason Halac
Managing Director, Dexcom Ventures
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Oura | Series D | $200M | Dec 2024 |
 Phenomix Sciences | Series A | $5.5M | May 2024 |
 Signos | Series B | $20M | Oct 2023 |
 Nutromics | Series A | $14M | Sep 2022 |
| Signos | Series A | $13M | Nov 2021 |
 myBiometry | Seed | $5M | — |
Top Co-Investors
GV2 shared
DCM Ventures2 shared
Fidelity Investments1 shared
Cheyenne Ventures1 shared
VU Venture Partners1 shared
Artesian1 shared
Elevate Ventures1 shared
Labcorp1 shared
Health2047 Capital Partners1 shared
Last updated: 8 September 2026